ondansetron has been researched along with Lassitude in 11 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The 5-hydroxytryptamine receptor type 3 antagonist ondansetron had a significant positive effect on fatigue in CHC." | 9.11 | Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. ( Antoun, Z; Benzaken, S; Caroli-Bosc, FX; Cherikh, F; Demarquay, JF; Gelsi, E; Huet, PM; Piche, T; Rampal, P; Renou, C; Rigault, MC; Tran, A; Vanbiervliet, G, 2005) |
| "A woman with chronic hepatitis C and profound fatigue became symptomfree when treated long-term with ondansetron 4 mg twice daily." | 9.09 | Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. ( Jones, EA, 1999) |
| "To examine non-clinical and clinical data relevant to the hypothesis that ondansetron, a 5-HT(3) receptor subtype antagonist, ameliorates pruritus and fatigue in liver disease." | 8.84 | Pruritus and fatigue associated with liver disease: is there a role for ondansetron? ( Jones, EA, 2008) |
| "Fatigue is common in primary biliary cirrhosis (PBC)." | 6.71 | A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. ( Burak, KW; Girlan, L; Heathcote, EJ; Heslegrave, RJ; Huet, PM; Swain, M; Theal, JJ; Tomlinson, GA; Toosi, MN, 2005) |
| " It is showed that the use of 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night is more effective in therapy for fatigue/weakness syndrome in incurable cancer patients compared to standard therapy." | 5.20 | [Optimization of pharmacological therapy for weakness syndrome in incurable patients]. ( Glushchenko, VA; Karitsky, AP; Kvashnin, AV; Rozengard, SA; Ryazankina, AA, 2015) |
| "The 5-hydroxytryptamine receptor type 3 antagonist ondansetron had a significant positive effect on fatigue in CHC." | 5.11 | Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. ( Antoun, Z; Benzaken, S; Caroli-Bosc, FX; Cherikh, F; Demarquay, JF; Gelsi, E; Huet, PM; Piche, T; Rampal, P; Renou, C; Rigault, MC; Tran, A; Vanbiervliet, G, 2005) |
| "A woman with chronic hepatitis C and profound fatigue became symptomfree when treated long-term with ondansetron 4 mg twice daily." | 5.09 | Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. ( Jones, EA, 1999) |
| "To examine non-clinical and clinical data relevant to the hypothesis that ondansetron, a 5-HT(3) receptor subtype antagonist, ameliorates pruritus and fatigue in liver disease." | 4.84 | Pruritus and fatigue associated with liver disease: is there a role for ondansetron? ( Jones, EA, 2008) |
| "The primary outcome was the incidence of postoperative nausea and vomiting (PONV) during the first postoperative day." | 2.84 | Randomized clinical trial of preoperative dexamethasone on postoperative nausea and vomiting after laparoscopy for suspected appendicitis. ( Gögenur, I; Kirkegaard, A; Kleif, J; Vilandt, J, 2017) |
| "Fatigue is common in primary biliary cirrhosis (PBC)." | 2.71 | A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. ( Burak, KW; Girlan, L; Heathcote, EJ; Heslegrave, RJ; Huet, PM; Swain, M; Theal, JJ; Tomlinson, GA; Toosi, MN, 2005) |
| "Ondansetron is a selective 5-hydroxytryptamine type 3 receptor antagonist effective as an antiemetic in patients experiencing post-operative or cancer chemotherapy-induced nausea and vomiting." | 2.67 | Ondansetron does not affect alfentanil-induced ventilatory depression or sedation. ( Dershwitz, M; Di Biase, PM; Joslyn, AF; Rosow, CE; Sanderson, PE; Wilson, RS, 1992) |
| "Profound fatigue is a clinically significant complication of chronic liver disease." | 1.33 | Personal view: a potential novel treatment for fatigue complicating chronic liver disease--how should its efficacy be evaluated? ( Jones, EA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ryazankina, AA | 1 |
| Rozengard, SA | 1 |
| Glushchenko, VA | 1 |
| Karitsky, AP | 1 |
| Kvashnin, AV | 1 |
| Sharma, A | 1 |
| Muresanu, DF | 1 |
| Lafuente, JV | 1 |
| Patnaik, R | 1 |
| Tian, ZR | 1 |
| Buzoianu, AD | 1 |
| Sharma, HS | 1 |
| Kleif, J | 1 |
| Kirkegaard, A | 1 |
| Vilandt, J | 1 |
| Gögenur, I | 1 |
| Theal, JJ | 1 |
| Toosi, MN | 1 |
| Girlan, L | 1 |
| Heslegrave, RJ | 1 |
| Huet, PM | 2 |
| Burak, KW | 1 |
| Swain, M | 1 |
| Tomlinson, GA | 1 |
| Heathcote, EJ | 1 |
| Revicki, DA | 1 |
| Piche, T | 1 |
| Vanbiervliet, G | 1 |
| Cherikh, F | 1 |
| Antoun, Z | 1 |
| Gelsi, E | 1 |
| Demarquay, JF | 1 |
| Caroli-Bosc, FX | 1 |
| Benzaken, S | 1 |
| Rigault, MC | 1 |
| Renou, C | 1 |
| Rampal, P | 1 |
| Tran, A | 1 |
| Jones, EA | 3 |
| Wilkes, G | 1 |
| Dershwitz, M | 1 |
| Di Biase, PM | 1 |
| Rosow, CE | 1 |
| Wilson, RS | 1 |
| Sanderson, PE | 1 |
| Joslyn, AF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dexamethasone Preoperative for Patients Undergoing Laparoscopy for Suspected Appendicitis[NCT02415335] | Phase 2 | 119 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ondansetron and Lassitude
| Article | Year |
|---|---|
Methodological issues and the measurement of fatigue in primary biliary cirrhosis.
Topics: Clinical Trials as Topic; Fatigue; Humans; Liver Cirrhosis, Biliary; Ondansetron; Serotonin Antagoni | 2005 |
Pruritus and fatigue associated with liver disease: is there a role for ondansetron?
Topics: Animals; Antipruritics; Central Nervous System; Evidence-Based Medicine; Fatigue; Humans; Liver Dise | 2008 |
6 trials available for ondansetron and Lassitude
| Article | Year |
|---|---|
[Optimization of pharmacological therapy for weakness syndrome in incurable patients].
Topics: Acetamides; Adamantane; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2015 |
Randomized clinical trial of preoperative dexamethasone on postoperative nausea and vomiting after laparoscopy for suspected appendicitis.
Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Appendectomy; Appendicitis; Dexamethasone; | 2017 |
A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue.
Topics: Constipation; Cross-Over Studies; Fatigue; Headache; Humans; Liver Cirrhosis, Biliary; Middle Aged; | 2005 |
Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Depression; Double-Blind Method; Fatigue; Female; Hep | 2005 |
Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; | 1999 |
Ondansetron does not affect alfentanil-induced ventilatory depression or sedation.
Topics: Alfentanil; Antiemetics; Fatigue; Humans; Imidazoles; Infusions, Intravenous; Male; Ondansetron; Pul | 1992 |
3 other studies available for ondansetron and Lassitude
| Article | Year |
|---|---|
Sleep Deprivation-Induced Blood-Brain Barrier Breakdown and Brain Dysfunction are Exacerbated by Size-Related Exposure to Ag and Cu Nanoparticles. Neuroprotective Effects of a 5-HT3 Receptor Antagonist Ondansetron.
Topics: Animals; Blood Proteins; Blood-Brain Barrier; Brain; Brain Chemistry; Brain Edema; Cognition Disorde | 2015 |
Personal view: a potential novel treatment for fatigue complicating chronic liver disease--how should its efficacy be evaluated?
Topics: Fatigue; Hepatitis C; Humans; Liver Cirrhosis, Biliary; Liver Diseases; Ondansetron; Randomized Cont | 2006 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipati | 2007 |